O'Dell Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

O'Dell Group’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	112
2022 Q3	$0	Hold	3	–	–	﹤0.01%	416
2022 Q2	$0	Hold	3	–	–	﹤0.01%	464
2022 Q1	$0	Hold	3	–	–	﹤0.01%	514
2021 Q4	$0	Sell	3 -7	-70%	-$600	﹤0.01%	513
2021 Q3	$1K	Buy	+10	New	+$1.01K	﹤0.01%	455

Other funds holding BIB

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

O'Dell Group's BIB Position: Q4 2022 in Review

O'Dell Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2022, closing a stake of 3 shares.

O'Dell Group first reported a position in BIB in Q3 2021 and held it in 5 quarters. The position peaked at $1K in Q3 2021. 25 funds tracked by Wall St. Rank hold BIB as of Q4 2022.

O'Dell Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2022 after selling out during the quarter.
O'Dell Group sold 3 ProShares Ultra NASDAQ Biotechnology shares in Q4 2022.
O'Dell Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2021 and held it in 5 quarters.
O'Dell Group's ProShares Ultra NASDAQ Biotechnology position peaked at $1K in Q3 2021.
25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2022.

Based on O'Dell Group's 13F filing for Q4 2022, filed 14 Feb 2023.